|
|
Found results for
 patents
1.
|
APPLICATION OF POLYCYCLIC AROMATIC COMPOUND IN THE PREPARATION OF ANTIFUNGAL DRUGS
| Document Number |
03224558 |
| Status |
Pending |
| Filing Date |
2022-05-24 |
| Open to Public Date |
2023-01-19 |
| Owner |
THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY (China)
|
| Inventor |
- Zhang, Hong
- Ye, Wencai
- Zhang, Yishan
- Hu, Lijun
- Li, Shuixiu
- Zhao, Yajing
- Tang, Chuanyan
- Weng, Luobang
|
Abstract
The present invention provides a polycyclic aryl compound S1 for preparing a drug for antifungal infection. The structural formula of the polycyclic compound is S1. The polycyclic aryl compound having the shell-core structure and represented by S1 in the present invention is suitable for preparing drugs for anti-Candida, Aspergillus, Mucor and other pathogenic fungal infections, and has the following beneficial effects: the compound S1 of the present application has a broad-spectrum antifungal effect on pathogenic fungi including, but not limited to, Candida, Aspergillus, Mucor, etc., is effective against azole resistant Candida, is low in toxicity to mammals, and can treat systemic fungal infection by oral administration, and can also be used locally to treat mucosal Candida infection.
|
2.
|
APPLICATION OF POLYCYCLIC ARYL COMPOUND IN PREPARATION OF ANTIFUNGAL DRUG
| Application Number |
CN2022094745 |
| Publication Number |
2023/284420 |
| Status |
In Force |
| Filing Date |
2022-05-24 |
| Publication Date |
2023-01-19 |
| Owner |
THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY (China)
|
| Inventor |
- Zhang, Hong
- Ye, Wencai
- Zhang, Yishan
- Hu, Lijun
- Li, Shuixiu
- Zhao, Yajing
- Tang, Chuanyan
- Weng, Luobang
|
Abstract
The present invention provides a polycyclic aryl compound S1 for preparing a drug for antifungal infection. The structural formula of the polycyclic compound is S1. The polycyclic aryl compound having the shell-core structure and represented by S1 in the present invention is suitable for preparing drugs for anti-Candida, Aspergillus, Mucor and other pathogenic fungal infections, and has the following beneficial effects: the compound S1 of the present application has a broad-spectrum antifungal effect on pathogenic fungi including, but not limited to, Candida, Aspergillus, Mucor, etc., is effective against azole resistant Candida, is low in toxicity to mammals, and can treat systemic fungal infection by oral administration, and can also be used locally to treat mucosal Candida infection.
IPC Classes ?
- C07D 295/194 - Radicals derived from thio- or thiono carboxylic acids
- A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/00 - Medicinal preparations characterised by special physical form
- A61P 31/10 - Antimycotics
|
|
